Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Sarcopenia - Global Pipeline Review, H2 2019 - ResearchAndMarkets.com

November 22, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 22, 2019--

The “Sarcopenia - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 12, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Featured News & Press Releases

  • Oct 31, 2019: Biophytis files protocol amendment to optimize the SARA-INT phase 2b clinical trial for sarcopenia
  • Oct 04, 2019: Biophytis opens 22nd clinical site in the SARA-INT phase 2b trial of Sarconeos (BIO101) for the treatment of sarcopenia
  • Feb 18, 2019: Biophytis announces three oral and one poster presentations at the 2019 International Conference on Frailty and Sarcopenia Research
  • Dec 07, 2018: BIOPHYTIS announces one oral presentation and two poster presentations at the 11th international conference on cachexia, sarcopenia and muscle wasting
  • Nov 27, 2018: BIOPHYTIS to host Key Opinion Leader Meeting on the biology of Aging and its application in Neuromuscular Diseases
  • Sep 04, 2018: Biophytis provides enrollment update in its phase 2b SARA-OBS and SARA-INT studies of Sarconeos in sarcopenia
  • May 24, 2018: BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia
  • Mar 01, 2018: BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami

Companies Mentioned

  • Biophytis SA
  • Faraday Pharmaceuticals Inc
  • Helixmith Co Ltd
  • Immusoft Corp
  • Keren Therapeutics
  • MYOS RENS Technology Inc
  • Neurotune AG
  • PhaseBio Pharmaceuticals Inc
  • ST Pharm Co Ltd
  • Teijin Pharma Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/x9bssd

View source version on businesswire.com:https://www.businesswire.com/news/home/20191122005328/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/22/2019 09:56 AM/DISC: 11/22/2019 09:56 AM